Theravance Biopharma Inc Aktie News

YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma incurs no commercial costs in China; Viatris is responsible for the launch and commercialization DUBLIN , June ...

Definitive agreement to result in one-time $225 million cash payment  Theravance Biopharma retains  rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today,  in addition to the $1.1 billion upfront received in 2022 , and up t...

DUBLIN , May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial officer Aine Miller - Head-Development Conference Call Participants Marc Frahm - TD Cowen Operator Hello, ladies and gentlemen. Good afternoon.

DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massach...

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 2024 1   TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 2024 2 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer Quarter-end cash balance of $131 million, with no debt Reaffirming all financial guidance metrics D...

DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts.  These analyses support the Company's understanding of ampreloxet...

DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.